1. BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies 
Beatriz E. Marciano, MD, Chiung-Yu Huang, PhD, Gyan Joshi, PhD, Nima Rezaei, MD, Beatriz Costa Carvalho, MD, Zoe Allwood, MD, Aydan Ikinciogullari, MD, Shereen M. Reda, MD, Andrew Gennery, MD, Vojtech Thon, MD, Francisco Espinosa-Rosales, MD, Waleed Al-Herz, MD, Oscar Porras, MD, Anna Shcherbina, MD, Anna Szaflarska, MD, Şebnem Kiliç, MD, Jose L. Franco, MD, PhD, Andrea C. Gómez Raccio, MD, Persio Roxo, MD, Isabel Esteves, MD, Nermeen Galal, MD, Anete Sevciovic Grumach, MD, PhD, Salem Al- Tamemi, MD, Alisan Yildiran, MD, Julio C. Orellana, MD, Masafumi Yamada, MD, Tomohiro Morio, MD, Diana Liberatore, MD, Yoshitoshi Ohtsuka, MD, Yu-Lung Lau, MD, Ryuta Nishikomori, MD, Carlos Torres-Lozano, MD, Juliana T.L. Mazzucchelli, MD, Maria M.S. Vilela, MD, Fabiola S. Tavares, MD, Luciana Cunha, MD, Jorge A. Pinto, MD, Sara E. Espinosa-Padilla, MD, Leticia Hernandez- Nieto, MD, Reem A. Elfeky, MD, Tadashi Ariga, MD, Heike Toshio, MD, Figen Dogu, MD, Funda Cipe, MD, Renata Formankova, MD, M. Enriqueta Nuñez-Nuñez, MD, Liliana Bezrodnik, MD, Jose Gonçalo Marques, MD, María I. Pereira, PhD, Viviana Listello, MD, Mary A. Slatter, MD, Zohreh Nademi, MD, Danuta Kowalczyk, MD, Thomas A. Fleisher, MD, Graham Davies, MD, Bénédicte Neven, MD, Sergio D. Rosenzweig, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 133, Issue 4, Pages (April 2014)
DOI: /j.jaci
Copyright © Terms and Conditions

2. Fig 1
BCG-vaccinated patients with SCID: epidemiologic characteristics. A, Age at SCID diagnosis. B, SCID diagnosis and BCG-associated complications (no manifestations or localized or disseminated complications). C, Age at BCG vaccination and BCG-associated complications (no manifestations or localized or disseminated complications) distribution. D, BCG vaccine strain and BCG-associated complications (no manifestations or localized or disseminated complications). E, Age at onset of BCG-associated complications (localized or disseminated complications). F, Site of involvement of disseminated BCG-associated complications. GI, Gastrointestinal; GU, genitourinary. X-axis, number of patients.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © Terms and Conditions

3. Fig 2
Time-to-event analysis by age at BCG vaccination and age at HSCT. A, Kaplan-Meier curves for the time from vaccination to death caused by BCG-associated complications comparing early (≤1 month of age, dashed line) versus late (>1 month of age, solid line) vaccination (P < .0001). B, Kaplan-Meier curves for the time from vaccination to death within 24 months of age before HSCT comparing early (≤1 month of age, dashed line) versus late (>1 month of age, solid line) vaccination (P = .01). C, Kaplan-Meier curves for time from HSCT to death comparing early (≤1 month of age, dashed line) versus late (>1 month of age, solid line) vaccination (P = .96). D, Kaplan-Meier curves for the time from HSCT to death comparing early (≤3 months of age, dashed line) versus late (>3 months of age, solid line) transplantation (P = .33).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © Terms and Conditions